- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Akums has announced a board meeting on 26th May 2025, approving audited consolidated and standalone financial results for FY25. Consolidated revenue rose to ₹4108 Cr, with a net profit of ₹34 Cr, bouncing back from last year’s loss. Strong operational cash flows of ₹465 Cr were reported despite flood-related costs. The recent IPO raised ₹637 Cr, mainly used for debt repayment, working capital, and acquisitions. Akums also launched a UK subsidiary to expand globally. Leadership update: Mr. Amrut Medhekar will step down as CEO of the CDMO business from 15th July 2025. Auditors were reshuffled, pending shareholder nod.
All announcements from Akums Drugs and Pharmaceuticals Limited